U.S. Equities1h ago
AbbVie's Vraylar Heads for IRA Price Cut in 2027; Imbruvica Already Down 26 Percent
AbbVie warned investors to model lower prices for its $4.2 billion psychiatry drug Vraylar starting in 2027 under Medicare price negotiation, as its cancer drug Imbruvica faces a 26 percent sales cliff from IRA pricing.